Literature DB >> 6800254

Alternative pathway of complement in multiple myeloma.

E H Kraut, A L Sagone.   

Abstract

The alternative pathway of complement was studied in 16 newly diagnosed and 2 previously treated patients with multiple myeloma. Functional activity of this pathway was abnormal in 10 of these 18 patients (55%). These abnormalities correlated with depressed levels of alternative pathway components in 3 of 10 patients, but in the remaining 7, no etiology was demonstrated. There was an inverse correlation between activity and concentration of the monoclonal protein. This defect is an additional factor that may predispose patients with myeloma to overwhelming infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800254     DOI: 10.1002/ajh.2830110402

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Protracted necrotizing pharyngitis associated with an acquired defect of neutrophil chemotaxis in multiple myeloma.

Authors:  K Bergsman; G Khatib; R Khatib; K Szwajkun
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

Review 2.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors.

Authors:  Toni Valković; Vedrana Gačić; Jelena Ivandić; Božo Petrov; Renata Dobrila-Dintinjana; Elizabeta Dadić-Hero; Antica Načinović-Duletić
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

Review 4.  Complement and macrophage crosstalk during process of angiogenesis in tumor progression.

Authors:  M Afzal Khan; A M Assiri; D C Broering
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410

Review 5.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

6.  Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets.

Authors:  Rodrigo Carlini Fernando; Fabricio de Carvalho; Diego Robles Mazzotti; Adriane Feijó Evangelista; Walter Moisés Tobias Braga; Maria de Lourdes Chauffaille; Adriana Franco Paes Leme; Gisele Wally Braga Colleoni
Journal:  Genes Cancer       Date:  2015-11

Review 7.  CD46 and Oncologic Interactions: Friendly Fire against Cancer.

Authors:  Michelle Elvington; M Kathryn Liszewski; John P Atkinson
Journal:  Antibodies (Basel)       Date:  2020-11-02

Review 8.  Role of hydrogen sulfide donors in cancer development and progression.

Authors:  Ebenezeri Erasto Ngowi; Attia Afzal; Muhammad Sarfraz; Saadullah Khattak; Shams Uz Zaman; Nazeer Hussain Khan; Tao Li; Qi-Ying Jiang; Xin Zhang; Shao-Feng Duan; Xin-Ying Ji; Dong-Dong Wu
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.